Comparison of Therapeutic Results with/without Additional Hyperbaric Oxygen Therapy in Idiopathic Sudden Sensorineural Hearing Loss: A Randomized Prospective Study.
Audiol Neurootol
; 26(1): 11-16, 2021.
Article
em En
| MEDLINE
| ID: mdl-32535600
ABSTRACT
OBJECTIVE:
To assess the efficacy of the combination of hyperbaric oxygen (HBO) and pharmacological treatment in patients with idiopathic sudden sensorineural hearing loss (ISSNHL) and define patients amenable for HBO therapy.METHODS:
Prospective, randomized, trial involving 136 cases with unilateral ISSNHL that were randomly divided into 2 groups the pharmacological treatment (P) group and HBO + pharmacological treatment (HBO+P) group, which received additional HBO for 14 days besides the pharmacological treatments. Pure tone audiometry gain larger than 15 dBHL was defined as success, and the success rate of each group was calculated.RESULTS:
The overall success rate of the HBO+P group and the P group is 60.6% (40/66) and 42.9% (30/70), respectively (p < 0.05). Furthermore, patients with mild-moderate baseline hearing loss, aged ≤50 years, receiving treatment in ≤14 days, or without accompanied dizziness/vertigo in the HBO+P group had higher success rate than the P group (p < 0.05).CONCLUSIONS:
HBO combined with pharmacological treatments leads to better hearing recovery than pharmacological treatments alone.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Medicinas Tradicionais:
Medicinas_tradicionales_de_asia
/
Medicina_china
Métodos Terapêuticos e Terapias MTCI:
Terapias_biologicas
/
Oxigenoterapia_hiperbrica
Assunto principal:
Vasodilatadores
/
Vitaminas
/
Prednisona
/
Flunarizina
/
Perda Auditiva Súbita
/
Glucocorticoides
/
Perda Auditiva Neurossensorial
/
Oxigenoterapia Hiperbárica
Tipo de estudo:
Clinical_trials
/
Observational_studies
Idioma:
En
Revista:
Audiol Neurootol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
China